<DOC>
	<DOCNO>NCT01224730</DOCNO>
	<brief_summary>This Phase I study analyze food-drug effect well QTc effect perifosine . Safety efficacy also evaluate . Patients complete first 24 day single agent perifosine may opportunity 1 ) continue single agent perifosine ; 2 ) switch combination capecitabine + perifosine ; 3 ) switch combination sorafenib + perifosine .</brief_summary>
	<brief_title>A Food Effect QTc Study Perifosine Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>Patients advanced malignancy Patients adequate organ marrow function Patients previously treat perifosine Patients receive chemotherapy , target agent , investigational agent device within four week ( 28 day ) prior Day 1 study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>